Propoxyphene/Acetaminophen

A to Z Drug Facts

Propoxyphene/Acetaminophen

  Action
  Indications
  Contraindications
  Route/Dosage
  Interactions
  Lab Test Interferences
  Adverse Reactions
  Precautions
Patient Care Considerations
  Administration/Storage
  Assessment/Interventions
  Patient/Family Education


(pro-POX-ee-feen/ass-cet-ah-MEE-noe-fen)
Propoxyphene HCl/Acetaminophen
Wygesic
Propoxyphene Napsylate/Acetaminophen
Darvocet-N 50, Darvocet-N 100, Propacet 100
Class: Narcotic analgesic combination

 Action Propoxyphene relieves pain by stimulating opiate receptors in CNS; also causes respiratory depression; peripheral vasodilation, inhibition of intestinal peristalsis, sphincter of Oddi spasm, stimulation of receptors that cause vomiting, increased bladder tone. Acetaminophen inhibits synthesis of prostaglandins; does not have significant anti-inflammatory effects or antiplatelet effects; produces antipyresis by direct action on the hypothalamic heat-regulating center.

 Indications Relief of mild-to-moderate pain; as analgesic-antipyretic in presence of aspirin allergy, hemostatic disturbances, bleeding diatheses, upper GI disease and gouty arthritis.

 Contraindications Standard considerations.

 Route/Dosage

PROPOXYPHENE NAPSYLATE

ADULTS: PO 100 mg (with 650 mg acetaminophen) q 4 hr prn; not to exceed 600 mg/day.

PROPOXYPHENE HYDROCHLORIDE

ADULTS: PO 65 mg (with 650 mg acetaminophen) q 4 hr; not to exceed 390 mg/day.

 Interactions

Carbamazepine: Increased carbamazepine serum levels; increased risk of acetaminophen hepatotoxicity. Charcoal: Decreased propoxyphene absorption. Cigarette smoking: Decreased propoxyphene effect because of liver enzyme induction. CNS depressants (alcohol, antidepressants, barbiturates, muscle relaxants, sedatives, tranquilizers): Increased CNS and respiratory depression. Hydantoins: Increased risk of acetaminophen hepatotoxicity. Sulfinpyrazone: Increased risk of acetaminophen hepatotoxicity. Warfarin: Potentiation of hypoprothrombinemic effect.

 Lab Test Interferences Increased amylase and lipase for up to 24 hr after administration.

 Adverse Reactions

CV: Hypotension. CNS: Lightheadedness; weakness; fatigue; sedation; dizziness; disorientation; uncoordination; paradoxical excitement; euphoria; dysphoria; insomnia. GI: Nausea; vomiting; constipation; anorexia; stomach pain; biliary spasm. GU: Urinary retention or hesitancy. RESP: Dyspnea; depression of cough reflex. OTHER: Tolerance; psychological and physical dependence with long-term use; histamine release; pain at injection site.

 Precautions

Pregnancy: Category C (D if used for prolonged periods). Lactation: Excreted in breast milk. Children: Safety and efficacy not established. Special-risk patients: Use with caution in patients with myxedema, acute alcoholism, acute abdominal conditions, ulcerative colitis, decreased respiratory reserve, head injury or increased cranial pressure, hypoxia, supraventricular tachycardia, depleted blood volume or circulatory shock. Drug dependence: Has abuse potential. Fatalities: Excessive doses, either alone or in combination with other CNS depressants (including alcohol), are major cause of drug-induced death. Do not use in patients who are suicidal or addiction prone. Hepatic and renal impairment: Use drug with caution; reduce total daily dosage; advise chronic alcoholics to limit acetaminophen intake to < 2 g/day.


PATIENT CARE CONSIDERATIONS


 Administration/Storage

 Assessment/Interventions

OVERDOSAGE: SIGNS & SYMPTOMS
  CNS depression (stupor to coma), respiratory depression, hypotension, seizures, pulmonary edema, cardiac arrhythmias, respiratory-metabolic acidosis, hepatitis

 Patient/Family Education

Books@Ovid
Copyright
© 2003 Facts and Comparisons
David S. Tatro
A to Z Drug Facts